In AD-relevant conditions, oligomeric Aβ and disease-associated shifts in APP processing appear to disrupt these homeostatic actions, resulting in reduced KCC2 function and weakened synaptic inhibition; boosting KCC2 expression or activity partially restores EGABA and improves synaptic and behavioral endpoints in preclinical models [127]. This evidence concerns the gene SLC12A5 and Alzheimer disease.